Drug profile · INN
lomefloxacin hydrochloride
MAXAQUIN
lomefloxacin hydrochloride (MAXAQUIN) is a bacterial dna gyrase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — lomefloxacin hydrochloride
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
lomefloxacin hydrochloride (MAXAQUIN) is a bacterial dna gyrase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Bacterial DNA gyrase inhibitor
Primary target: Bacterial DNA gyrase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is lomefloxacin hydrochloride?
lomefloxacin hydrochloride (MAXAQUIN) is a bacterial dna gyrase inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for lomefloxacin hydrochloride?
MAXAQUIN is a marketed brand name for lomefloxacin hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of lomefloxacin hydrochloride?
lomefloxacin hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.